An FDA expedited review pathway that accelerates drug approval if preliminary evidence suggests substantial improvement over existing treatments for serious conditions.
Breakthrough Therapy Designation (BTD) is a regulatory fast-track established by the FDA under the 2012 FDASIA (FDA Safety and Innovation Act) to accelerate development and review of drugs addressing serious or life-threatening conditions. The designation requires preliminary clinical evidence suggesting the drug demonstrates substantial improvement over existing therapies. While intended to serve patients with unmet medical needs, BTD does not guarantee safety or efficacy; it merely reduces the standard review timeline from 10 months to 6 months and allows more frequent FDA interaction during development.
Since inception, over 500 drugs have received BTD status, raising questions about whether accelerated review adequately protects public health. In 2020, remdesivir received BTD and Emergency Use Authorization (EUA) for COVID-19 based on limited trial data showing modest reduction in hospitalization duration; it later became widely used despite insufficient evidence of mortality benefit. Aducanumab, an Alzheimer's drug, received BTD in 2015 and accelerated approval in 2021 despite controversy over its clinical trial design and efficacy, leading to its withdrawal in 2023 after insurers refused reimbursement. The pathway illustrates the tension between accelerating access for patients and ensuring rigorous safety evaluation before widespread adoption.
